FDA-Approved dialysis device under Long-Term watch

NCT ID NCT07146854

Recruiting now Disease control Sponsor: Phraxis, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tracks 150 adults with end-stage kidney disease who use the EndoForce System to connect a dialysis graft to a vein. The device is already FDA-approved, so this is not an experiment—it's a check on long-term safety and how well it works over time. Researchers will monitor for complications like infections or blockages and measure how long the graft stays usable for dialysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EndoForce System (device for connecting hemodialysis graft to vein)
What this could lead to: If successful, this study could confirm that the EndoForce System is a safe and reliable option for hemodialysis access in kidney failure patients.
What could go wrong: This is an observational study, not a test of a new treatment. The device is already approved, so no major breakthroughs are expected. Risks include device-related complications like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE (ESRD)

Contacts and locations

Locations

MUSC Health Orangeburg
NOT_YET_RECRUITING

Orangeburg, South Carolina, 29118, United States
Spartanburg Regional Medical Center
RECRUITING

Spartanburg, South Carolina, 29303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.